- Tryp Therapeutics is a pharmaceutical company focused on establishing new drug candidates that will provide effective alternatives to established treatments for responding to medical conditions with largely unmet needs
- The company is preparing to launch a clinical trial with a 25mg synthetic psychedelic drug candidate, TRP-8802, to determine its efficacy and safety in treating select eating disorders in combination with psychotherapy
- Tryp recently announced that its educational partner, Fluence, has completed training of the psychotherapists who will be involved in administering the drug candidate to help establish minimal variability in the data outcomes and grant the patients the best possible experience
- Investment banking services provider, Ladenburg Thalmann & Co., announced on Aug. 26 that it has initiated coverage on Tryp with a “buy” rating
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is approaching the launch of its phase 2a clinical trial that will use synthetic psilocybin (a psychedelic drug derived from certain mushrooms) in combination with psychotherapy for a select class of overeating disorders.
Tryp has continued to execute on its mission to develop successful treatments with increased efficacy for medical conditions with high unmet needs. The phase 2a trial, to be conducted at the University of Florida (“UF”), will determine safety and efficacy of psilocybin on hyperphagia — a condition in which the patients never feel full, so they are continually wanting to eat.
“The research we’re actually going to be doing at the University of Florida with psilocybin is focusing on a little bit more intense problems than just eating disorders,” said pediatric eating disorders expert Dr. Jennifer Miller, who will be the trial’s principal investigator, during an interview with The Dales Report in May (https://ibn.fm/XDAVY). “Ultimately, of course, we hope it will help people with overall eating disorders, but first we’re going to focus on people with specific neurologic causes of those eating disorders … for treatment of a select chronic eating disorder called Prader-Willi Syndrome (‘PWS’).”
The hyperphagia trial will also target hypothalamic obesity eating disorder — the result of the removal of a brain tumor — and binge eating disorder. TRP-8802, an off-the-shelf synthetic psilocybin active pharmaceutical ingredient (“API”) will aim to shake up the clinical thinking on how to deal with such neurological conditions and prepare Tryp for further studies using their novel, trademarked drug candidate, TRP-8803.
“All of the currently available approved obesity and eating disorder medications are daily medications: you stop taking them, you stop having the efficacy,” Miller said. “Our hope is with psilocybin, … (that) once- or twice-a-year treatments will allow these neural networks to rewire themselves and provide a more chronic treatment, which doesn’t exist right now. … None of the currently available treatments or even past available treatments touch their appetite and fullness.”
On Aug. 24, Tryp announced that psychedelic therapy educational platform partner Fluence, has completed the training of the psychotherapists who will be involved in the phase 2a trial by assisting and overseeing dosing sessions of the psychedelics (https://ibn.fm/eCpNN).
“Psychotherapy is an integral part of Tryp’s novel treatment methods to create the proper mindset for the neuroplasticity benefits of psilocybin to take full effect,” the news release states. “Participants will undergo preparatory psychotherapy sessions with trained therapists leading to two dosing sessions in the upcoming phase 2a clinical trial for eating disorders. … Following the administration of the drug, patients will also benefit from multiple integration sessions with the therapists.”
To ensure the scientific viability of the trials, it is important to establish definitive guidelines and training to minimize variability and grant the patients the best possible experience. The training will also be adapted to subsequent clinical trials, such as using Tryp’s API to treat fibromyalgia and other chronic pain indications.
Tryp’s efforts have caught the attention of investment banking and capital markets products and services provider Ladenburg Thalmann & Co. Inc., which serves investors who are specifically focused on health care and life sciences companies. Ladenburg Thalmann announced on Aug. 26 that it had initiated coverage on Tryp with a buy rating (https://ibn.fm/9aFSD).
In its research note, Ladenburg noted that psychedelics have recently outperformed approved prescription treatments for major depressive disorder and posttraumatic stress disorder, leading to the advisement that psilocybin-assisted psychotherapy may provide an appropriate response for helping people with eating disorders “benefit from a disconnect of the brain’s neural connections, allowing for new connections and behaviors distinct from current memories and feelings.”
For more information on Tryp Therapeutics, visit the company’s website at www.TrypTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.